1186610-03-6

Basic information

• Product Name: 3-oxo-3-(tetrahydrofuran-3-yl)propanenitrile
• Synonyms: 3-oxo-3-(tetrahydrofuran-3-yl)propanenitrile;3-oxo-3-(oxolan-3-yl)propanenitrile;3-Oxo-3-(tetrahydro-furan-3-yl)-propionitrile
• CAS NO: 1186610-03-6
• Molecular Formula: C7H9NO2
• Molecular Weight: 139.16
• Mol File: 1186610-03-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 250.5±30.0 °C(Predicted)
• Appearance: /
• Density: 1.150±0.06 g/cm3(Predicted)
• PKA: 9.11±0.20(Predicted)
• CAS DataBase Reference: 3-oxo-3-(tetrahydrofuran-3-yl)propanenitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-oxo-3-(tetrahydrofuran-3-yl)propanenitrile(1186610-03-6)
• EPA Substance Registry System: 3-oxo-3-(tetrahydrofuran-3-yl)propanenitrile(1186610-03-6)

Safety Data

• Hazardous Substances Data: 1186610-03-6(Hazardous Substances Data)

Upstream product

• 89364-31-8 3-tetrahydrofuroic acid 
• 53662-85-4 methyl tetrahydrofuran-3-carboxylate 
• 75-05-8 acetonitrile 

Downstream Products

• 1186609-16-4 5-(tetrahydrofuran-3-yl)-1H-pyrazol-3-amine 
• 1574357-76-8 1-(4-((2-((1H-indazol-5-yl)amino)pyrimidin-4-yl)oxy)naphthalen-1-yl)-3-(1-(4-methoxyphenyl)-3-(tetrahydrofuran-3-yl)-1H-pyrazol-5-yl)urea 

Relevant articles and documents

MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN

Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disease where modulation of Myc family proteins is desired. Also disclosed herein are methods of using said compounds and compositions.

3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS

The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. (I) In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.

SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals, in particular their use in the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders.